Sciety

Sciety focuses on early-stage life-science companies originating in the Nordic region. The portfolio targets drug development, diagnostics, medical devices, and digital-health platforms. Its position pages indicate an emphasis on precision oncology, including companies working on minimal residual disease detection.

The firm spans seed through growth-stage investments, with initial checks calibrated to biotech's capital requirements. Unlike generalist seed funds, Sciety reserves meaningful follow-on capacity to support companies through clinical trials and regulatory processes. Later-stage participation may include co-investments alongside larger specialist healthcare funds.

Sciety concentrates on the Nordic life-science cluster, drawing origination from relationships with Karolinska Institutet, Swedish university hospitals, and regional biotech incubators. The proximity to Stockholm's research infrastructure provides access to spinouts and academic founders before they reach international syndicate desks.

Sciety participates in syndicates and co-investment structures where later-stage specialist healthcare investors join Nordic rounds. The firm may lead rounds at seed or act as a local anchor for international syndicates seeking Nordic exposure. Specific co-investors are disclosed on a per-deal basis.

Sciety operates as an asset manager registered in Sweden, raising capital targeted at Nordic life-science venture. Available sources do not confirm whether it manages a single flagship fund, parallel vehicles, or deal-by-deal SPVs. The regulatory and operational structure is consistent with a dedicated venture capital manager rather than a multi-asset platform.